Project Grant R01DK137800
Award Date
9/1/24
Completion Date
6/30/27
Dollars Obligated
$316K
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
This Project Grant award of $117,000 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is funding research to delineate the role of substance P-mediated activation of mast cells in irritable bowel syndrome (IBS) pathophysiology. The key objectives are to determine the mechanisms of substance P-induced colonic mast cell activation and elucidate the contributions of mast...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $196,940 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 5-year study on a positive psychology intervention for irritable bowel syndrome (IBS). The project aims to examine the feasibility, acceptability, and preliminary efficacy of a 9-week phone-based positive...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $604,082 to Duke University to assess the use of psyllium, a soluble fiber, in mitigating fructan-induced gastrointestinal symptoms in children with irritable bowel syndrome (IBS). The key objectives are to: 1) investigate the effect of psyllium at two different doses on microbial fructan fermentation when...
This Project Grant award of $1,328,326.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on the regulation of CD39 expression in gamma delta intraepithelial lymphocytes (gd IELs) and its impact on immunometabolism and function. The research aims to elucidate the mechanisms by which CD39 expression is regulated in gd IELs, understand the coupling between CD39 and gd IEL...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $790,359 to the University of North Carolina at Chapel Hill to develop a targeted probiotic yeast therapy for treating inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis. The project aims to design, characterize, and optimize a bioengineered Saccharomyces boulardii yeast that can...
This Project Grant award, totaling $233,600.00 and spanning September 1, 2024 to June 30, 2027, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award supports high-throughput functional analyses of genetic drivers of inflammatory bowel disease (IBD), a debilitating condition characterized by chronic inflammation and erosion of intestinal functions. The...
This federal Project Grant award of $637,000.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to explore the production and signaling properties of novel bile acids produced by the gut microbiome. The project aims to 1) define the microbiology of microbially conjugated bile acid (MCBA) production, 2) determine the agonist activity of MCBAs on the...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $584,750 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to Foli Bio Inc. on September 17, 2024. The grant will fund the development and validation of Foli Bio's "EXFO-SEQ" technology, a non-invasive platform to analyze the exfoliome (RNA content exfoliated from intestinal cells) in stool samples. The goal is to generate insights into gene expression...
This National Science Foundation (NSF) Project Grant, awarded under the Computer and Information Science and Engineering (CISE) program (CFDA 47.070), provides $168,690 to the Florida Institute of Technology Inc. (Florida TECH) to develop a theragnostic (therapeutic + diagnostic) system for inflammatory bowel diseases (IBD). The project aims to model the complex interplay of host, microbial, and environmental factors that trigger IBD using data science, and then leverage synthetic biology and...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) provides $1,255,725 to the Icahn School of Medicine at Mount Sinai to develop manufacturing technologies and advance defined live biotherapeutic products (LBPs) for the treatment of recurrent Clostridioides difficile infection (rCDI) and ulcerative colitis. The key objectives are to: 1) develop a solid-state fermentation platform to enable rapid, scalable manufacturing of defined...